In 2005, a breakthrough study first illustrated the efficacy of single-agent PARP inhibitor treatment with Olaparib in BRCA-mutated ovarian cancer, paving the way for further investigation of PARP inhibitors as a future mainstay of cancer treatment (12). This evidence concerns the gene PARP1 and ovarian cancer.